Upstream Bio, Inc.
UPBUpstream Bio, Inc. in brief
Upstream Bio, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $229 M on 13 October 2026, which makes it the 15,769th largest listed company in the world and the 3,070th largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net loss of $143 M. It employs about 75 people and Everett Rand Sutherland is its chief executive. Its shares trade under the symbol UPB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Upstream Bio, Inc.
We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma, including a long-term safety and efficacy extension study, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. We reported positive top-line results in our CRSwNP Phase 2 trial in September 2025 and positive top-line results in our severe asthma Phase 2 trial in February 2026. We initiated our Phase 2 COPD trial in July 2025. We plan to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027, prioritizing a Phase 3 development strategy that focuses on maximizing efficacy in both indications, without biomarker restriction, with quarterly at-home administration. Our experienced team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care.
From the company's annual report filed with the US SEC: read the report
Upstream Bio, Inc. timeline
- 2024
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 11 October 2024; shares registered for exchange trading on 8 October 2024.
- 2025
- 💰Record revenue of $3 millionFY2025, the highest of the 3 years on record.
Events of Upstream Bio, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,691 (Aug 2026) · #3,052 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 79.9×
- Price / book
- 0.7×
- Free cash flow yield
- -58.4%
- Net margin (TTM)
- -5731.8%
- Operating margin
- -5626.7%
- Return on equity
- -48.2%
- Liabilities / assets
- 4.0%
- Revenue growth
- +20.3%
- R&D / revenue
- 4800.4%
- Revenue per employee
- $38 K
- Profit per employee
- $-1.9 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3M | +20.3% | $-160M | $-143M | -5033.0% |
| Dec 2024 | $2M | -0.4% | $-78M | $-63M | -2650.2% |
| Dec 2023 | $2M | — | $-40M | $-21M | -863.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-133M | $0M | $-133M | $-2.66 | — |
| Dec 2024 | $-59M | $1M | $-60M | $-5.58 | — |
| Dec 2023 | $-38M | $0M | $-38M | $-12.95 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (-41.2% on a year earlier), net income $-41M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 1, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jun 10, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 16, 2026DEF 14AProxy statement
- Mar 26, 20268-KCurrent reportMaterial agreement
- Mar 26, 202610-KAnnual report · period to Dec 2025
- Mar 26, 20268-KCurrent reportResults of operations
Official filings of Upstream Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $3 M
- Operating income
- $-160 M
- Net income
- $-143 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $354 M
- Total liabilities
- $14 M
- Total equity
- $340 M
As of December-2025
Top 100 institutional investors in Upstream Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 8,181,586 | +18,689 (+0.23%) | 14.93% | $43 M | Nov 10, 2026 |
| 2 | Orbimed Advisors LLC | 5,693,589 | 0 (0.00%) | 10.39% | $30 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 3,687,310 | -66,048 (-1.76%) | 6.73% | $19 M | Nov 13, 2026 |
| 4 | Decheng Capital LLC | 2,724,868 | 0 (0.00%) | 4.97% | $14 M | Nov 13, 2026 |
| 5 | Enavate Sciences GP, LLC | 2,459,703 | 0 (0.00%) | 4.49% | $13 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 1,959,338 | +82,604 (+4.40%) | 3.57% | $10 M | Nov 13, 2026 |
| 7 | Jpmorgan Chase & Co | 1,458,685 | +446,641 (+44.13%) | 2.66% | $8 M | Nov 12, 2026 |
| 8 | D. E. Shaw & Co., Inc. | 1,398,735 | +362,691 (+35.01%) | 2.55% | $7 M | Nov 16, 2026 |
| 9 | Millennium Management LLC | 1,168,181 | +24,406 (+2.13%) | 2.13% | $6 M | Nov 16, 2026 |
| 10 | Goldman Sachs Group Inc | 1,126,897 | +879,980 (+356.39%) | 2.06% | $6 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 972,580 | +41,319 (+4.44%) | 1.77% | $5 M | Nov 6, 2026 |
| 12 | Qube Research & Technologies Ltd | 926,237 | -52,263 (-5.34%) | 1.69% | $5 M | Nov 13, 2026 |
| 13 | SEB Asset Management AB | 878,473 | 0 (0.00%) | 1.60% | $5 M | Nov 4, 2026 |
| 14 | Woodline Partners LP | 831,481 | 0 (0.00%) | 1.52% | $4 M | Nov 16, 2026 |
| 15 | Trexquant Investment LP | 766,231 | +299,801 (+64.28%) | 1.40% | $4 M | Nov 16, 2026 |
| 16 | Vanguard Portfolio Management LLC | 755,981 | +43,314 (+6.08%) | 1.38% | $4 M | Nov 13, 2026 |
| 17 | State Street Corp | 736,488 | -29,835 (-3.89%) | 1.34% | $4 M | Nov 12, 2026 |
| 18 | BNP Paribas Financial Markets | 730,278 | +218,732 (+42.76%) | 1.33% | $4 M | Nov 12, 2026 |
| 19 | Y-Intercept (Hong Kong) Ltd | 642,574 | -50,981 (-7.35%) | 1.17% | $3 M | Oct 16, 2026 |
| 20 | Morgan Stanley | 635,905 | +111,273 (+21.21%) | 1.16% | $3 M | Nov 13, 2026 |
| 21 | Parkman Healthcare Partners LLC | 618,056 | -317,191 (-33.92%) | 1.13% | $3 M | Nov 16, 2026 |
| 22 | Voleon Capital Management LP | 477,306 | +192,072 (+67.34%) | 0.87% | $3 M | Nov 16, 2026 |
| 23 | Two Sigma Investments, LP | 428,190 | +385,865 (+911.67%) | 0.78% | $2 M | Nov 16, 2026 |
| 24 | AQR Capital Management LLC | 415,734 | -129,135 (-23.70%) | 0.76% | $2 M | Nov 16, 2026 |
| 25 | Dimensional Fund Advisors LP | 374,836 | -6,777 (-1.78%) | 0.68% | $2 M | Nov 4, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Point72 Asset Management, L.P. | 372,823 | -80,188 (-17.70%) | 0.68% | $2 M | Nov 16, 2026 |
| 27 | Acadian Asset Management LLC | 370,395 | +195,285 (+111.52%) | 0.68% | $2 M | Nov 9, 2026 |
| 28 | HRT Financial LP | 347,991 | +177,401 (+103.99%) | 0.63% | $2 M | Nov 13, 2026 |
| 29 | Bank Of America Corp /de/ | 345,802 | -45,960 (-11.73%) | 0.63% | $2 M | Nov 16, 2026 |
| 30 | Wellington Management Group LLP | 342,353 | 0 (0.00%) | 0.62% | $2 M | Nov 16, 2026 |
| 31 | Charles Schwab Investment Management Inc | 338,278 | +75,822 (+28.89%) | 0.62% | $2 M | Nov 16, 2026 |
| 32 | Propel Bio Management, LLC | 335,389 | -15,000 (-4.28%) | 0.61% | $2 M | Nov 13, 2026 |
| 33 | Sphera Funds Management LTD. | 325,831 | +106,131 (+48.31%) | 0.59% | $2 M | Nov 16, 2026 |
| 34 | Schonfeld Strategic Advisors LLC | 302,433 | +76,673 (+33.96%) | 0.55% | $2 M | Nov 16, 2026 |
| 35 | Samsara Biocapital, LLC | 300,361 | -53,356 (-15.08%) | 0.55% | $2 M | Nov 16, 2026 |
| 36 | Northern Trust Corp | 288,894 | -8,452 (-2.84%) | 0.53% | $2 M | Nov 16, 2026 |
| 37 | Squarepoint Ops LLC | 275,746 | -15,158 (-5.21%) | 0.50% | $1 M | Nov 9, 2026 |
| 38 | Vanguard Fiduciary Trust Co | 269,677 | +30,061 (+12.55%) | 0.49% | $1 M | Nov 13, 2026 |
| 39 | XTX Topco Ltd | 225,453 | -16,893 (-6.97%) | 0.41% | $1 M | Nov 16, 2026 |
| 40 | Jump Financial, LLC | 201,395 | -21,828 (-9.78%) | 0.37% | $1 M | Nov 13, 2026 |
| 41 | Barclays PLC | 198,213 | +169,005 (+578.63%) | 0.36% | $1 M | Nov 6, 2026 |
| 42 | Renaissance Technologies LLC | 194,700 | +63,400 (+48.29%) | 0.36% | $1 M | Nov 12, 2026 |
| 43 | Arrowstreet Capital, Limited Partnership | 189,832 | -167,924 (-46.94%) | 0.35% | $1 M | Nov 13, 2026 |
| 44 | UBS Group AG | 158,109 | -76,605 (-32.64%) | 0.29% | $1 M | Nov 10, 2026 |
| 45 | Jacobs Levy Equity Management, Inc | 155,028 | -98,064 (-38.75%) | 0.28% | $1 M | Nov 16, 2026 |
| 46 | Walleye Capital LLC | 154,727 | -343,763 (-68.96%) | 0.28% | $1 M | Nov 13, 2026 |
| 47 | Marshall Wace, LLP | 135,771 | New | 0.25% | $1 M | Nov 13, 2026 |
| 48 | Los Angeles Capital Management LLC | 132,805 | +110,420 (+493.28%) | 0.24% | $1 M | Nov 12, 2026 |
| 49 | Quantinno Capital Management LP | 112,795 | +57,957 (+105.69%) | 0.21% | $1 M | Nov 13, 2026 |
| 50 | EntryPoint Capital, LLC | 105,924 | -23,522 (-18.17%) | 0.19% | $1 M | Nov 13, 2026 |
| 51 | Bank of New York Mellon Corp | 97,148 | +11,401 (+13.30%) | 0.18% | $1 M | Nov 5, 2026 |
| 52 | Man Group plc | 88,782 | +14,959 (+20.26%) | 0.16% | $0 M | Nov 16, 2026 |
| 53 | American Century Companies Inc | 87,423 | +9,229 (+11.80%) | 0.16% | $0 M | Nov 12, 2026 |
| 54 | Nuveen, LLC | 86,987 | +2,217 (+2.62%) | 0.16% | $0 M | Nov 10, 2026 |
| 55 | HSBC Holdings PLC | 81,500 | +70,707 (+655.12%) | 0.15% | $0 M | Nov 16, 2026 |
| 56 | Invesco Ltd. | 72,988 | +19,591 (+36.69%) | 0.13% | $0 M | Nov 12, 2026 |
| 57 | Alps Advisors Inc | 72,045 | +16,817 (+30.45%) | 0.13% | $0 M | Nov 3, 2026 |
| 58 | Algert Global LLC | 69,650 | -48,980 (-41.29%) | 0.13% | $0 M | Nov 17, 2026 |
| 59 | Fox Run Management, L.L.C. | 69,504 | New | 0.13% | $0 M | Nov 12, 2026 |
| 60 | Simplify Asset Management Inc. | 62,113 | 0 (0.00%) | 0.11% | $0 M | Oct 27, 2026 |
| 61 | Gsa Capital Partners LLP | 61,020 | -8,328 (-12.01%) | 0.11% | $0 M | Nov 16, 2026 |
| 62 | Vestcor Inc | 59,404 | New | 0.11% | $0 M | Nov 12, 2026 |
| 63 | Citadel Advisors LLC | 59,042 | New | 0.11% | $0 M | Nov 16, 2026 |
| 64 | ExodusPoint Capital Management, LP | 55,027 | +13,982 (+34.07%) | 0.10% | $0 M | Nov 16, 2026 |
| 65 | Virtus Investment Advisers, LLC | 52,022 | -1,616 (-3.01%) | 0.09% | $0 M | Nov 12, 2026 |
| 66 | Russell Investments Group, Ltd. | 48,130 | +587 (+1.23%) | 0.09% | $0 M | Nov 6, 2026 |
| 67 | Alliancebernstein L.P. | 45,600 | -6,080 (-11.76%) | 0.08% | $0 M | Nov 16, 2026 |
| 68 | Allspring Global Investments Holdings, LLC | 44,947 | +1,765 (+4.09%) | 0.08% | $0 M | Nov 4, 2026 |
| 69 | Rhumbline Advisers | 42,445 | +61 (+0.14%) | 0.08% | $0 M | Nov 10, 2026 |
| 70 | Mercer Global Advisors Inc /adv | 39,187 | +25,835 (+193.49%) | 0.07% | $0 M | Nov 16, 2026 |
| 71 | Jane Street Group, LLC | 36,350 | +20,756 (+133.10%) | 0.07% | $0 M | Nov 12, 2026 |
| 72 | Citigroup Inc | 35,733 | -4,606 (-11.42%) | 0.07% | $0 M | Nov 4, 2026 |
| 73 | Entropy Technologies, LP | 34,366 | +16,824 (+95.91%) | 0.06% | $0 M | Nov 13, 2026 |
| 74 | Strs Ohio | 30,600 | +18,600 (+155.00%) | 0.06% | $0 M | Oct 30, 2026 |
| 75 | Deutsche Bank AG\ | 28,891 | -212,556 (-88.03%) | 0.05% | $0 M | Nov 6, 2026 |
| 76 | Canada Pension Plan Investment Board | 28,600 | +17,100 (+148.70%) | 0.05% | $0 M | Nov 16, 2026 |
| 77 | Price T Rowe Associates Inc /MD/ | 28,058 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 78 | Tudor Investment Corp Et Al | 26,755 | New | 0.05% | $0 M | Nov 16, 2026 |
| 79 | Aquatic Capital Management LLC | 23,543 | New | 0.04% | $0 M | Nov 16, 2026 |
| 80 | MetLife Investment Management, LLC | 21,429 | +577 (+2.77%) | 0.04% | $0 M | Nov 16, 2026 |
| 81 | WINTON GROUP Ltd | 19,800 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 82 | Savant Capital, LLC | 18,164 | New | 0.03% | $0 M | Nov 6, 2026 |
| 83 | Shay Capital LLC | 18,000 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 84 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 17,099 | +882 (+5.44%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Creative Planning | 15,456 | -13,027 (-45.74%) | 0.03% | $0 M | Nov 2, 2026 |
| 86 | Axq Capital, LP | 14,325 | -12,743 (-47.08%) | 0.03% | $0 M | Nov 12, 2026 |
| 87 | Graham Capital Management, L.P. | 14,137 | -8,371 (-37.19%) | 0.03% | $0 M | Nov 16, 2026 |
| 88 | Aigen Investment Management, LP | 13,327 | New | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Vanguard Global Advisers, LLC | 13,221 | +162 (+1.24%) | 0.02% | $0 M | Nov 13, 2026 |
| 90 | Verdad Advisers, LP | 11,550 | -10,260 (-47.04%) | 0.02% | $0 M | Nov 16, 2026 |
| 91 | PDT Partners, LLC | 11,500 | New | 0.02% | $0 M | Nov 16, 2026 |
| 92 | Manufacturers Life Insurance Company, The | 11,328 | -4,407 (-28.01%) | 0.02% | $0 M | Nov 13, 2026 |
| 93 | Voya Investment Management LLC | 10,834 | New | 0.02% | $0 M | Nov 10, 2026 |
| 94 | Mariner, LLC | 10,523 | -22,618 (-68.25%) | 0.02% | $0 M | Nov 12, 2026 |
| 95 | China Universal Asset Management Co., Ltd. | 9,994 | +1,333 (+15.39%) | 0.02% | $0 M | Oct 28, 2026 |
| 96 | Police & Firemen's Retirement System of New Jersey | 9,456 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 97 | Wells Fargo & Company/mn | 7,395 | -22,102 (-74.93%) | 0.01% | $0 M | Nov 16, 2026 |
| 98 | New York State Common Retirement Fund | 5,200 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 99 | Arax Advisory Partners | 4,734 | +2,963 (+167.31%) | 0.01% | $0 M | Nov 12, 2026 |
| 100 | Legal & General Group Plc | 3,795 | -8,766 (-69.79%) | 0.01% | $0 M | Nov 16, 2026 |
Mutual funds holding Upstream Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.44 M | $10 M | 2.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 1.37 M | $9 M | 2.5% | 0.10% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 1.32 M | $8 M | 2.4% | 0.11% | no change | Jul 31, 2026 |
| 🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC | 800,000 | $7 M | 1.5% | 0.12% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 921,063 | $6 M | 1.7% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 965,800 | $6 M | 1.8% | 0.13% | no change | Jul 31, 2026 |
| 🇸🇪 SEB LäkemedelsfondSEB Funds AB | 878,473 | $6 M | 1.6% | 0.34% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 693,618 | $4 M | 1.3% | 0.10% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 691,003 | $4 M | 1.3% | 0.20% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 341,675 | $3 M | 0.62% | 0.05% | no change | May 29, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 386,877 | $3 M | 0.71% | <0.01% | +0.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 400,000 | $3 M | 0.73% | 0.08% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 384,509 | $2 M | 0.70% | <0.01% | +18% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 338,261 | $2 M | 0.62% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 234,657 | $2 M | 0.43% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 256,130 | $2 M | 0.47% | 0.02% | +20% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 234,635 | $2 M | 0.43% | 0.05% | +141% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 177,681 | $1 M | 0.32% | <0.01% | +0.4% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 168,486 | $1 M | 0.31% | <0.01% | +3.9% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 161,663 | $1 M | 0.29% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 168,915 | $1 M | 0.31% | 0.20% | +41% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 136,560 | $1 M | 0.25% | <0.01% | −17% | May 31, 2026 |
| 🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC | 145,000 | $1 M | 0.26% | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 150,504 | $1 M | 0.27% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC | 132,200 | $1 M | 0.24% | 0.05% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 131,691 | $1 M | 0.24% | 0.06% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 72,472 | $1 M | 0.13% | <0.01% | +79% | May 31, 2026 |
| 🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC | 93,712 | $1 M | 0.17% | 0.04% | +1.6% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 64,388 | $1 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 84,939 | $1 M | 0.15% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 62,606 | $1 M | 0.11% | 0.02% | −23% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC | 75,300 | $0 M | 0.14% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 55,699 | $0 M | 0.10% | 0.29% | +16% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 73,550 | $0 M | 0.13% | <0.01% | +162% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC | 69,306 | $0 M | 0.13% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 51,794 | $0 M | 0.09% | <0.01% | +4.9% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 61,682 | $0 M | 0.11% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 56,530 | $0 M | 0.10% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 55,900 | $0 M | 0.10% | <0.01% | +1.7% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 49,678 | $0 M | 0.09% | 0.03% | −5.8% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 49,639 | $0 M | 0.09% | <0.01% | +2.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 49,342 | $0 M | 0.09% | 0.02% | +21% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 46,924 | $0 M | 0.09% | <0.01% | +24% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 35,347 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 39,624 | $0 M | 0.07% | <0.01% | +211% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 36,047 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 33,698 | $0 M | 0.06% | <0.01% | +89% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 25,380 | $0 M | 0.05% | 0.02% | +4.7% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 30,052 | $0 M | 0.05% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC | 28,913 | $0 M | 0.05% | 0.11% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 26,407 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 28,718 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 24,780 | $0 M | 0.05% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 20,416 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 23,300 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 20,425 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 20,337 | $0 M | 0.04% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 21,000 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 18,296 | $0 M | 0.03% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 17,113 | $0 M | 0.03% | 0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 17,030 | $0 M | 0.03% | <0.01% | +68% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 14,079 | $0 M | 0.03% | <0.01% | +1010% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 13,073 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 17,310 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 16,828 | $0 M | 0.03% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Vanguard Growth And Income FundWellington Management Company LLP | 15,200 | $0 M | 0.03% | <0.01% | −42% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 14,836 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 12,699 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 12,553 | $0 M | 0.02% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 10,120 | $0 M | 0.02% | 0.03% | −13% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 12,221 | $0 M | 0.02% | 0.03% | −14% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 12,184 | $0 M | 0.02% | <0.01% | +1.4% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 11,100 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 8,875 | $0 M | 0.02% | <0.01% | new | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 11,605 | $0 M | 0.02% | <0.01% | +395% | Jul 31, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 11,496 | $0 M | 0.02% | <0.01% | +3.0% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 9,449 | $0 M | 0.02% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 10,145 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 8,389 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 7,520 | $0 M | 0.01% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 8,066 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 7,632 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,522 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 5,295 | $0 M | <0.01% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 5,200 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 6,674 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 5,986 | $0 M | 0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 5,900 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 6,279 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 5,514 | $0 M | 0.01% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 5,311 | $0 M | <0.01% | <0.01% | +44% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 5,300 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 5,366 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 4,879 | $0 M | <0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 4,040 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,193 | $0 M | <0.01% | <0.01% | +28% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,809 | $0 M | <0.01% | <0.01% | +190% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,666 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 2,529 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 2,959 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Upstream Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Aaron DeykinChief Medical Officer | Sell | -895 | $5.490 | $5 K | 32,302 | Form 4 |
| filed | Everett Rand SutherlandChief Executive Officer, Director | Sell | -2,095 | $5.490 | $12 K | 68,717 | Form 4 |
| filed | Allison AmbroseGeneral Counsel | Sell | -485 | $5.490 | $3 K | 15,563 | Form 4 |
| filed | Michael GrayCFO and COO | Sell | -853 | $5.490 | $5 K | 27,942 | Form 4 |
| filed | Adam HoughtonChief Business Officer | Sell | -700 | $5.490 | $4 K | 22,901 | Form 4 |
| filed | Everett Rand SutherlandChief Executive Officer, Director | Sell | -2,095 | $6.100 | $13 K | 70,812 | Form 4 |
| filed | Adam HoughtonChief Business Officer | Sell | -700 | $6.100 | $4 K | 23,601 | Form 4 |
| filed | Allison AmbroseGeneral Counsel | Sell | -477 | $6.100 | $3 K | 16,048 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Upstream Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1.049-for-1 split
Fails to deliver
- : 800 shares at $4.17
- : 10,112 shares at $5.04
- : 7,300 shares at $5.04
- : 704 shares at $6.69
- : 4,012 shares at $6.61
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Upstream Bio, Inc. scorecard#
Passes 4 of the 13 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median79.9×Price to sales 79.9× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-58.4%Free cash flow is -58.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year20.2%Revenue up 20.2% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.66 vs -5.58Diluted EPS -2.66 in fiscal 2025 against -5.58 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$143 MNet income -$143 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-35.4%-35.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities26.2×Current ratio 26.16 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone8.13Z-score 8.13 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year293.6%Diluted shares up 293.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Upstream Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 2.9+20.4%100% | 2.4−0.4%100% | 2.4—100% | |
| Research and development | 137+117%4793% | 63+98.0%2657% | 32—1336% | |
| General and administrative | 26+53.8%925% | 17+60.5%724% | 11—449% | |
| Operating expenses | 163+104%5719% | 80+88.6%3381% | 42—1785% | |
| Operating income | −160—−5619% | −78—−3281% | −40—−1685% | |
| Interest and finance income | 17+39.7%593% | 12+191%512% | 4.2—175% | |
| Other non-operating income (expense) | 17+13.1%593% | 15−23.6%631% | 20—823% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −143—−5026% | −63—−2650% | −21—−863% | |
| Net income attributable to shareholders | −143—−5026% | −63—−2650% | −21—−863% | |
| Earnings per share, basic | -2.66—— | -5.58—— | -12.95—— | |
| Earnings per share, diluted | -2.66—— | -5.58—— | -12.95—— | |
| Shares, weighted average (basic) | 54+294%— | 14+363%— | 3.0—— | |
| Shares, weighted average (diluted) | 54+294%— | 14+363%— | 3.0—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 102−68.8%28.7% | 326+1162%67.7% | 26—22.0% | |
| Short-term investments | 240+66.0%67.8% | 145+72.1%30.0% | 84—71.7% | |
| Receivables | 0.7+9.0%0.2% | 0.6+526%0.1% | 0.1—0.1% | |
| Other current assets | 0.7r9.6−91.0%0.2% | 8.1+14.2%1.7% | 7.1—6.0% | |
| Current assets | 352−26.6%99.4% | 479+310%99.5% | 117—99.8% | |
| Property, plant and equipment | 0.6−4.0%0.2% | 0.6+266%0.1% | 0.2—0.1% | |
| Right-of-use (leased) assets | 1.2−31.5%0.3% | 1.8+4047%0.4% | 0.0—0.0% | |
| Goodwill | — | 0—0.0% | — | |
| Total assets | 354−26.6%100% | 482+311%100% | 117—100% | |
| Accounts payable | 2.7−32.5%0.8% | 4.0+103%0.8% | 2.0—1.7% | |
| Current liabilities | 13+25.3%3.8% | 11+64.8%2.2% | 6.5—5.6% | |
| Lease liabilities (non-current) | 0.5−51.4%0.2% | 1.1—0.2% | — | |
| Total liabilities | 14+18.0%4.0% | 12+26.4%2.5% | 9.4—8.0% | |
| Retained earnings | −334—−94.5% | −191—−39.6% | −128—−109% | |
| Shareholders' equity | 340−27.7%96.0% | 470—97.5% | −123—−105% | |
| Total liabilities and equity | 354−26.6%100% | 482+311%100% | 117—100% | |
| Shares outstanding | 54+1.2%— | 54+1691%— | 3.0—— | |
| Cash-flow statement | ||||
| Depreciation and amortization | 0.2+111%6.6% | 0.1+48.3%3.8% | 0.1—2.5% | |
| Share-based compensation | 10+72.1%362% | 6.0+80.6%253% | 3.3—140% | |
| Cash from operating activities | −133—−4670% | −59—−2497% | −38—−1594% | |
| Capital expenditure | −0.2—−5.8% | −0.5—−21.6% | −0.1—−6.1% | |
| Cash from investing activities | −93—−3275% | −59—−2510% | −83—−3481% | |
| Cash from financing activities | 2.4−99.4%85.5% | 419+223%17676% | 130—5443% | |
| Change in cash | −224−175%−7860% | 300+3319%12669% | 8.8—369% | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2.9+2.5%100% | 0.4−42.2%100% | 0.8−17.5%100% | 1.0+82.7%100% | 0.7*+9.0%100% | 0.7+12.5%100% | 0.9—100% | 0.6—100% | 0.6*—100% | 0.6—100% | |
| Research and development | 149+26.2%5207% | 37+11.0%9268% | 36−4.7%4669% | 37+41.7%3536% | 40*+84.5%6013% | 33+114%4828% | 38—4041% | 26—4558% | 22*—3552% | 15—2543% | |
| General and administrative | 29+16.3%1009% | 7.2+29.3%1814% | 7.1−4.9%912% | 8.1+19.2%782% | 6.7*+29.2%998% | 5.5+36.3%811% | 7.4—792% | 6.8—1198% | 5.2*—841% | 4.1—670% | |
| Operating expenses | 178+24.5%6216% | 44+13.6%11082% | 43−4.7%5581% | 45+37.0%4318% | 47*+73.9%7011% | 39+97.5%5639% | 45—4833% | 33—5756% | 27*—4393% | 20—3213% | |
| Operating income | −176—−6116% | −43—−10982% | −42—−5481% | −44—−4218% | −46*—−6911% | −38—−5539% | −44—−4733% | −32—−5656% | −26*—−4293% | −19—−3113% | |
| Interest and finance income | 12−36.8%404% | 2.2−45.7%565% | 2.7−40.0%344% | 3.1−35.6%295% | 3.7*−28.0%547% | 4.1+41.4%601% | 4.4—473% | 4.7—838% | 5.1*—828% | 2.9—478% | |
| Other non-operating income (expense) | 12−36.6%404% | 2.2−46.5%554% | 2.7−39.1%345% | 3.0−36.2%292% | 3.7*−27.0%555% | 4.1+40.8%598% | 4.4—468% | 4.7—838% | 5.1*—828% | 2.9—478% | |
| Income tax | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | — | |
| Net income including minority interests | −164—−5712% | −41*—−10428% | −40*—−5136% | −41—−3926% | −42*—−6356% | −34*—−4941% | −40*—−4265% | −27—−4818% | −21*—−3465% | — | |
| Net income attributable to shareholders | −164—−5712% | −41—−10428% | −40—−5136% | −41—−3926% | −42*—−6356% | −34—−4941% | −40—−4265% | −27—−4818% | −21*—−3465% | −16—−2635% | |
| Earnings per share, basic | — | -0.75—— | -0.73—— | -0.75—— | — | -0.63—— | -0.74—— | -0.51—— | — | -6.96—— | |
| Earnings per share, diluted | — | -0.75—— | -0.73—— | -0.75—— | — | -0.63—— | -0.74—— | -0.51—— | — | -6.96—— | |
| Shares, weighted average (basic) | 55+1.6%— | 55+1.6%— | 55+1.5%— | 54+1.3%— | — | 54+1684%— | 54—— | 54—— | — | 3.0—— | |
| Shares, weighted average (diluted) | 55+1.6%— | 55+1.6%— | 55+1.5%— | 54+1.3%— | — | 54+1684%— | 54—— | 54—— | — | 3.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 47—19.3% | 47−34.3%19.3% | 79+74.7%28.2% | 97+35.6%30.4% | 102−68.8%28.7% | 72+119%18.4% | 45—10.8% | 71—15.6% | 326—67.7% | 33—14.2% | |
| Short-term investments | 160—65.0% | 160−46.7%65.0% | 182−47.7%64.7% | 198−45.1%62.2% | 240+66.0%67.8% | 300+60.0%76.8% | 348—82.8% | 360—78.9% | 145—30.0% | 188—80.7% | |
| Receivables | 0.4—0.2% | 0.4−42.2%0.2% | 0.8−17.6%0.3% | 1.0+82.7%0.3% | 0.7+9.0%0.2% | 0.7+12.5%0.2% | 0.9—0.2% | 0.6—0.1% | 0.6—0.1% | 0.6—0.3% | |
| Other current assets | 0.8—0.3% | 0.8−95.0%0.3% | 1.2−95.1%0.4% | 21−5.4%6.5% | 0.7r9.6−91.0%0.2% | 16+165%4.1% | 24—5.6% | 22—4.8% | 8.1—1.7% | 6.0—2.6% | |
| Current assets | 245—99.4% | 245−37.1%99.4% | 280−33.2%99.4% | 316−30.3%99.4% | 352−26.6%99.4% | 389+71.2%99.4% | 418—99.5% | 454—99.5% | 479—99.5% | 227—97.7% | |
| Property, plant and equipment | 0.4—0.2% | 0.4−33.3%0.2% | 0.5−15.4%0.2% | 0.5−5.4%0.2% | 0.6−4.0%0.2% | 0.6+6.6%0.2% | 0.5—0.1% | 0.5—0.1% | 0.6—0.1% | 0.6—0.2% | |
| Right-of-use (leased) assets | 0.8—0.3% | 0.8−44.9%0.3% | 0.9−39.4%0.3% | 1.1−35.1%0.3% | 1.2−31.5%0.3% | 1.4−28.5%0.3% | 1.5—0.4% | 1.6—0.4% | 1.8—0.4% | 1.9—0.8% | |
| Goodwill | — | — | — | — | — | — | — | — | 0—0.0% | — | |
| Total assets | 246—100% | 246−37.1%100% | 281−33.1%100% | 318−30.3%100% | 354−26.6%100% | 391+68.1%100% | 421—100% | 456—100% | 482—100% | 233—100% | |
| Accounts payable | 2.4—1.0% | 2.4−39.7%1.0% | 2.3−9.3%0.8% | 1.7−63.8%0.5% | 2.7−32.5%0.8% | 4.0−19.3%1.0% | 2.6—0.6% | 4.7—1.0% | 4.0—0.8% | 4.9—2.1% | |
| Current liabilities | 12—4.9% | 12+0.4%4.9% | 10.0−8.6%3.6% | 14+42.9%4.3% | 13+25.3%3.8% | 12+9.5%3.0% | 11—2.6% | 9.6—2.1% | 11—2.2% | 11—4.7% | |
| Lease liabilities (non-current) | 0.1—0.0% | 0.1−91.9%0.0% | 0.2−73.4%0.1% | 0.4−60.7%0.1% | 0.5−51.4%0.2% | 0.7−44.3%0.2% | 0.8—0.2% | 1.0—0.2% | 1.1—0.2% | 1.3—0.5% | |
| Total liabilities | 12—4.9% | 12−4.7%4.9% | 10−13.3%3.6% | 14+33.1%4.4% | 14+18.0%4.0% | 13+3.9%3.2% | 12—2.8% | 11—2.3% | 12—2.5% | 12—5.2% | |
| Retained earnings | −456—−185% | −456—−185% | −415—−147% | −375—−118% | −334—−94.5% | −292—−74.6% | −258—−61.4% | −218—−47.8% | −191—−39.6% | −170—−72.9% | |
| Shareholders' equity | 234—95.1% | 234−38.2%95.1% | 271−33.7%96.4% | 304−31.8%95.6% | 340−27.7%96.0% | 379—96.8% | 409—97.2% | 446—97.7% | 470—97.5% | −160—−68.9% | |
| Total liabilities and equity | 246—100% | 246−37.1%100% | 281−33.1%100% | 318−30.3%100% | 354−26.6%100% | 391+68.1%100% | 421—100% | 456—100% | 482—100% | 233—100% | |
| Shares outstanding | 55—— | 55+1.5%— | 55+1.8%— | 54+1.5%— | 54+1.2%— | 54+1685%— | 54—— | 54—— | 54—— | 3.0—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2+13.9%7.1% | 0.0*+6.5%12.4% | 0.1*+19.0%6.5% | 0.0+14.0%4.7% | 0.1*+16.3%8.5% | 0.0*—6.7% | 0.0*—4.5% | 0.0—7.6% | 0.0*—8.0% | — | |
| Share-based compensation | 16+59.9%552% | 4.3+67.5%1100% | 4.4+67.7%563% | 4.6+76.4%449% | 2.5*+20.1%375% | 2.6+39.2%380% | 2.6—277% | 2.6—466% | 2.1*—340% | 1.9—307% | |
| Cash from operating activities | −168—−5865% | −54*—−13729% | −36*—−4608% | −48—−4628% | −31*—−4585% | −22*—−3256% | −39*—−4188% | −41—−7273% | −20*—−3199% | — | |
| Capital expenditure | — | 0*—0.0% | — | — | −0.1*—−8.1% | −0.1*—−9.4% | — | — | −0.2*—−30.2% | — | |
| Cash from investing activities | 139—4853% | 22*−54.0%5615% | 16*+23.4%2039% | 42—4101% | 59*+40.6%8824% | 48*—7055% | 13*—1363% | −213—−37700% | 42*—6837% | — | |
| Shares issued | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | — | — | |
| Cash from financing activities | 4.3−98.4%150% | 0.1*−90.9%17.5% | 2.5*+314%328% | 0.6—57.8% | 1.1*−99.6%165% | 0.8*—111% | 0.6*—65.3% | −0.0—−6.0% | 271*—44151% | — | |
| Change in cash | −25−163%−862% | −32*−220%−8096% | −17*—−2242% | −4.9—−469% | 29*−90.0%4403% | 27*—3910% | −26*—−2759% | −255—−44979% | 293*—47789% | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Upstream Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
H-1B hiring at Upstream Bio, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $193 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Regulatory AffairsRegulatory Affairs Managers | 1 | $193 K |
Where: Waltham, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Upstream Bio, Inc.
How Upstream Bio, Inc. compares in Biotechnology
- Market cap$229 M · higher than 46% of 726
- Revenue$3 M · higher than 32% of 647
- Revenue growth20.3% · higher than 62% of 438
- Price / sales79.9× · lower than 12% of 339
- Price / book0.7× · lower than 86% of 534
- FCF yield-58.4% · higher than 20% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Upstream Bio, Inc.🇺🇸 | $229 M | — | — | +20.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 13, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 20, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Upstream Bio, Inc.? Verify and update this profile — free
Show Upstream Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.